Durability and Safety of Imeglimin as an Add-On to DPP-4 Inhibitors in Japanese Type 2 Diabetes: The 104-Week FAMILIAR Trial.
Diabetes Obes MetabJul 19, 2026 (epub)
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto et al.
✦ AI-curated · Sources linked
In 30 seconds
The FAMILIAR trial evaluated the long-term efficacy and safety of imeglimin as an add-on to DPP-4 inhibitors in Japanese patients with type 2 diabetes over 104 weeks. This multicenter, randomized controlled trial found that patients receiving imeglimin maintained a significant HbA1c reduction of -0.55% from baseline (p < 0.001) at week 104, with elderly patients showing stable control without hypoglycemic events.
Key findings
- Patients receiving imeglimin maintained a significant HbA1c reduction of -0.55% at week 104.
- Elderly patients (≥ 65 years) in the early-start group maintained stable HbA1c reduction of -0.58%.
- MTT analysis showed sustained improvements in glucose AUC and insulin sensitivity over time.
Why it matters
This study highlights the potential of imeglimin as a durable and safe option for improving glycemic control in patients with type 2 diabetes, particularly among the elderly, who are often at higher risk for hypoglycemia.